文献速递泌尿生殖MR

临床-定量MRI模型预测PI-RADS 3病灶临床显著性前列腺癌

Development and Validation of a Clinical-Quantitative MRI Model for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions.
PubMed 文献 · Acad Radiol · 2026-01-12

本研究回顾性纳入151例PI-RADS 3分病变患者,依据病理分为临床显著性前列腺癌(csPCa)组与非csPCa组,按7:3随机分为训练集与验证集。基于合成MRI(syMRI)定量参数与ADC值构建定量参数模型、临床模型及联合模型。训练集中联合模型AUC达0.91,优于临床模型(0.76)与定量参数模型(0.84),可辅助PI-RADS 3病灶活检决策。

要点

  • PI-RADS 3病灶中,前列腺体积(PV)、PSAD、T2值与ADC值是csPCa的独立预测因素。
  • 联合临床与定量MRI参数的模型诊断效能最高,训练集AUC为0.91(95%CI 0.86-0.97)。
  • syMRI定量T2值与ADC值可作为PI-RADS 3病灶危险分层的影像依据。

核心结论

  • 基于syMRI的临床-定量参数联合模型可有效识别PI-RADS 3病灶中的临床显著性前列腺癌,指导活检决策并减少不必要的有创操作。

研究设计与样本

  • 单中心回顾性研究,纳入151例PI-RADS 3分病变患者,按病理结果分为csPCa组与非csPCa组。
  • 患者按7:3比例随机分为训练集与验证集,以病理结果为参考标准。
  • 定量参数T1、T2、质子密度(PD)值来自合成MRI(syMRI)定量图,ADC值来自ADC图。
  • 采用单因素与多因素logistic回归筛选独立预测因素,分别构建临床模型、定量参数模型与联合模型。

关键影像表现/征象

  • 前列腺体积(PV)与前列腺特异性抗原密度(PSAD)为csPCa的独立临床预测因素。
  • syMRI定量T2值与ADC值为csPCa的独立影像预测因素。

诊断标准与关键数值

  • 训练集中联合模型AUC为0.91(95%CI 0.86-0.97),临床模型AUC为0.76(95%CI 0.66-0.85),定量参数模型AUC为0.84(95%CI 0.76-0.93)。
  • 联合模型与临床模型比较P=0.001,联合模型与定量参数模型比较P=0.017(DeLong检验)。
  • 决策曲线分析显示联合模型较单独临床模型或定量参数模型提供更高的净临床获益。

临床应用与阅片要点

  • 对PI-RADS 3病灶,可在报告中加入syMRI定量T2值与ADC值,辅助评估csPCa风险。
  • 结合前列腺体积与PSAD等临床指标可进一步提高对PI-RADS 3病灶的危险分层准确性。

局限性

  • 研究为单中心回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: This study aimed to develop and validate a clinical-MRI quantitative parameter model to predict clinically significant prostate cancer (csPCa) in PI-RADS score 3 lesions.

METHODS: A retrospective analysis was performed on 151 patients with PI-RADS score 3 lesions, divided into csPCa and non-csPCa groups according to pathological results. Patients were randomly assigned into training and validation cohorts in a 7:3 ratio. Quantitative values of T1, T2, and proton density (PD) were obtained from the synthetic magnetic resonance imaging (syMRI) quantitative maps, while apparent diffusion coefficient (ADC) values were derived from ADC maps. Independent predictors were identified using univariate and multivariate logistic regression analyses, based on which a quantitative parameter model was established. Clinical risk factors were used to construct a clinical model, and a combined model integrating both clinical and imaging predictors was developed. The predictive performance of the models was evaluated using the area under the curve (AUC), calibration curves, and decision curve analysis (DCA). The DeLong test was applied to compare the diagnostic efficiency between models.

RESULTS: Multivariate logistic regression analysis revealed that prostate volume (PV) and prostate-specific antigen density (PSAD) were independent clinical predictors for csPCa, while T2 and ADC values were independent imaging predictors. In the training cohort, the combined model achieved an AUC of 0.91 (95% CI: 0.86-0.97), outperforming the clinical model (AUC = 0.76, 95% CI: 0.66-0.85, P = 0.001) and the quantitative parameter model (AUC = 0.84, 95% CI: 0.76-0.93, P = 0.017). DCA demonstrated that the combined model provided greater net clinical benefit compared to either model alone.

CONCLUSION: The clinical-quantitative parameter combined model can effectively identify csPCa within PI-RADS score 3 lesions based on syMRI, thereby guiding biopsy decisions, reducing unnecessary invasive procedures, and improving patients' quality of life.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wang, Tang, Duan, et al. Development and Validation of a Clinical-Quantitative MRI Model for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions. Acad Radiol. 2026. PMID: 41530028. doi:10.1016/j.acra.2025.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。